SNTI

Senti Biosciences (SNTI)

Senti Biosciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SNTI

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/16	22:00	GlobeNewswire Inc.	Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics	NASDAQ:SNTI	Senti Biosciences Inc
2024/12/04	10:00	GlobeNewswire Inc.	Senti Biosciences Announces New Employment Inducement Grants	NASDAQ:SNTI	Senti Biosciences Inc
2024/12/02	21:10	GlobeNewswire Inc.	Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing	NASDAQ:SNTI	Senti Biosciences Inc
2024/12/02	21:02	GlobeNewswire Inc.	Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML	NASDAQ:SNTI	Senti Biosciences Inc
2024/12/02	21:00	GlobeNewswire Inc.	Senti Bio Appoints Fran Schulz to Board of Directors	NASDAQ:SNTI	Senti Biosciences Inc
2024/11/15	06:05	GlobeNewswire Inc.	Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights	NASDAQ:SNTI	Senti Biosciences Inc
2024/09/03	21:15	GlobeNewswire Inc.	Senti Bio to Participate in Upcoming Investor Conferences	NASDAQ:SNTI	Senti Biosciences Inc
2024/08/14	05:05	GlobeNewswire Inc.	Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights	NASDAQ:SNTI	Senti Biosciences Inc
2024/08/05	21:05	GlobeNewswire Inc.	Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202	NASDAQ:SNTI	Senti Biosciences Inc
2024/07/16	21:30	GlobeNewswire Inc.	Senti Bio Announces Reverse Stock Split	NASDAQ:SNTI	Senti Biosciences Inc
2024/07/01	21:05	GlobeNewswire Inc.	Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/30	05:14	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/30	05:09	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/30	05:07	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/18	06:19	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/18	06:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/13	21:15	GlobeNewswire Inc.	Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/10	05:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNTI	Senti Biosciences Inc
2024/05/10	05:05	GlobeNewswire Inc.	Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights	NASDAQ:SNTI	Senti Biosciences Inc
2024/04/30	21:05	GlobeNewswire Inc.	Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	NASDAQ:SNTI	Senti Biosciences Inc
2024/03/22	05:05	GlobeNewswire Inc.	Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	NASDAQ:SNTI	Senti Biosciences Inc
2024/01/06	06:05	GlobeNewswire Inc.	Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	NASDAQ:SNTI	Senti Biosciences Inc
2023/12/22	20:30	GlobeNewswire Inc.	Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	NASDAQ:SNTI	Senti Biosciences Inc
2023/11/14	06:15	GlobeNewswire Inc.	Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	NASDAQ:SNTI	Senti Biosciences Inc
2023/11/07	06:05	GlobeNewswire Inc.	Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	NASDAQ:SNTI	Senti Biosciences Inc
2023/10/31	22:06	GlobeNewswire Inc.	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	NASDAQ:SNTI	Senti Biosciences Inc
2023/09/27	22:05	GlobeNewswire Inc.	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting	NASDAQ:SNTI	Senti Biosciences Inc
2023/09/27	05:05	GlobeNewswire Inc.	Senti Bio to Participate in Upcoming Conferences	NASDAQ:SNTI	Senti Biosciences Inc
2023/09/05	21:30	GlobeNewswire Inc.	Senti Bio to Participate in Upcoming Investor Conferences	NASDAQ:SNTI	Senti Biosciences Inc
2023/08/11	21:35	GlobeNewswire Inc.	Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates	NASDAQ:SNTI	Senti Biosciences Inc